Prostatype Genomics secures about 70% coverage for upcoming warrant exercise, targeting up to SEK 12.5 million

• Prostatype Genomics secured about 70% coverage for the upcoming TO6 warrant exercise, totaling SEK 8.7 million of a SEK 12.5 million maximum.
• TO6 exercise window runs Sept. 1–15, 2026; last trading day is Sept. 11, 2026.
• Each TO6 entitles holders to subscribe for one new share at SEK 0.1, implying proceeds of up to SEK 12.5 million.
• Coverage includes a SEK 6 million top-down underwriting from Vator Securities, activated if exercise falls below 100%.
• Full exercise would add 125,225,546 shares, lifting total shares to 685,317,051; dilution would be about 18.3%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prostatype Genomics AB published the original content used to generate this news brief on August 31, 2026, and is solely responsible for the information contained therein.